We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
-26.15%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$114M
AUM Growth
+$34.8M
Cap. Flow
+$22.4M
Cap. Flow %
19.64%
Top 10 Hldgs %
76.84%
Holding
142
New
26
Increased
18
Reduced
48
Closed
32

Sector Composition

Rank Sector Weight
1 Miscellaneous 71.22%
2 Healthcare 15.92%
3 Industrials 2.97%
4 Technology 2.61%
5 Communication Services 2.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
LFWD icon
26
ReWalk Robotics
LFWD
$20M
$530K 0.47%
8,304
-2,178
-21% -$159K
VINC
27
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$510K 0.45%
25,000
-278
-1% -$5.24K
GLBS icon
28
Globus Maritime Ltd
GLBS
$77.3M
$496K 0.44%
472,652
-34,007
-7% -$42.9K
ADTX
29
DELISTED
ADITXT INC
ADTX
0
ZVRA icon
30
PUT
Zevra Therapeutics
ZVRA
$686M
$411K 0.36%
896
-3,244
-78% -$16.5K
GEVO icon
31
Gevo
GEVO
$388M
$411K 0.36%
+216,269
New +$456K
NEPT
32
DELISTED
Neptune Wellness Solutions Inc. Ordinary Shares
NEPT
$345K 0.3%
+27,398
New +$1.03M
ZVRA icon
33
Zevra Therapeutics
ZVRA
$686M
$321K 0.28%
70,000
-178,592
-72% -$907K
WLDSW icon
34
Wearable Devices Ltd Warrant
WLDSW
$170K
$320K 0.28%
3,665
+242
+7% +$28K
ATNM icon
35
CALL
Actinium Pharmaceuticals
ATNM
$39.6M
$307K 0.27%
+288
New +$2.92K
ATXI
36
DELISTED
Avenue Therapeutics, Inc. Common Stock
ATXI
$306K 0.27%
+3,520
New +$638K
OG
37
DELISTED
Onion Global Limited American Depositary Shares (each ten (10) ADSs representing one (1) Class A Ordinary Share)
OG
$300K 0.26%
1,200,489
-513,200
-30% -$133K
WLDS icon
38
Wearable Devices
WLDS
$3.98M
$299K 0.26%
951
-82
-8% -$43.5K
BEATW icon
39
Heartbeam Inc Warrant
BEATW
$22K
$296K 0.26%
271,788
-127,362
-32% -$102K
AMPG icon
40
AmpliTech
AMPG
$101M
$287K 0.25%
135,482
-900
-0.7% -$1.98K
PMCB icon
41
PharmaCyte Biotech
PMCB
$4.17M
$287K 0.25%
97,978
-469,622
-83% -$1.34M
SHFS icon
42
SHF Holdings
SHFS
$1.77M
$285K 0.25%
+8,028
New +$553K
APDNW
43
PUT
DELISTED
Applied DNA Sciences Inc Warrant
APDNW
$271K 0.24%
1,633
+236
+17% +$39.2K
BBLG
44
Bone Biologics
BBLG
$1.49M
$259K 0.23%
+859
New +$484K
BNBX
45
DELISTED
BNB PLUS CORP
BNBX
$253K 0.22%
10
+1
+11% +$24.2K
GWAV icon
46
Greenwave Technology Solutions
GWAV
$2.25M
$243K 0.21%
17
-2
-11% -$39.4K
AGMH icon
47
AGM Group Holdings
AGMH
$2.66M
$239K 0.21%
2,897
-3,083
-52% -$251K
IBIO icon
48
iBio
IBIO
$77.2M
$218K 0.19%
+24,523
New +$830K
RIBT
49
DELISTED
RiceBran Technologies
RIBT
$212K 0.19%
+284,798
New +$340K
AWH
50
DELISTED
Aspira Women's Health Inc. Common Stock
AWH
$199K 0.17%
39,873
-64,779
-62% -$354K

Similar funds

Sabby Management's Q4 2022 Portfolio in Review

As of Q4 2022, Sabby Management held 142 positions worth $114M, up 44% from $79.3M the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Sabby Management deployed $22.4M of net new capital in Q4 2022, opening 26 new positions and adding to 18 existing holdings. Its largest new stake was TuanChe: 8,098 shares worth $2.03M.

By sector, the portfolio is most concentrated in Miscellaneous at 71% of assets, up from 46% a quarter earlier, followed by Healthcare and Industrials.

On the sell side, the largest reduction was Bright Green Corporation Common Stock, an estimated $1.68M trimmed.

  • Sabby Management's largest Q4 2022 buy was TuanChe: 8,098 shares worth $2.03M.
  • Sabby Management added most to ToughBuilt Industries, Inc. Common Stock in Q4 2022, an estimated $1.21M increase.
  • Sabby Management's biggest Q4 2022 reduction was Bright Green Corporation Common Stock, cutting an estimated $1.68M.
  • Sabby Management fully exited Meta Materials Inc. Common Stock in Q4 2022, selling an estimated $1.82M.
  • Sabby Management's ten largest holdings make up 77% of its $114M portfolio in Q4 2022.
  • Sabby Management opened 26 new positions and closed 32 in Q4 2022.
  • Sabby Management's portfolio value rose 44% quarter-over-quarter to $114M.

Based on Sabby Management's 13F filing for Q4 2022, filed 14 Feb 2023.